Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 193

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines

Open access
Blanco, Belén, Pérez-Simón, José A., Sánchez-Abarca, Luis I., Carvajal-Vergara, Xonia, Mateos, Juan, Vidriales, Belén, López-Holgado, Natalia, Maiso, Patricia, Alberca, Mercedes, Villarón, Eva, Schenkein, David, Pandiella, Atanasio, Miguel, Jesús San · 2006 · Blood

Abstract

We explored the ability of the proteasome inhibitor bortezomib, which prevents nuclear factor κB (NF-κB) activation, to block T-cell activation, proliferation, and survival within alloreactive compared with resting T cells. For this purpose, T cells were stimulated with PHA, αCD3/αCD28, or allogeneic dendritic cells or through mixed lymphocyte cultures. NF-κB expression increased in activated T lymphocytes compared with resting T cells. Of interest, the higher the NF-κB expression, the more intense the proliferative blockade induced by bortezomib. Moreover, after mixed lymphocyte reaction (MLR) cultures, alloreactive T cells were 2 logs more sensitive to bortezomib-induced apoptosis than the resting T-cell counterpart. This effect was due to a selective induction of apoptosis among activated T cells that was related to caspase activation and cleavage of the antiapoptotic bcl-2 protein and was partially abolished by the addition of the pancaspase inhibitor Z-VAD-FMK. In addition, after secondary MLR, the number of activated T cells was significantly reduced among T lymphocytes previously cultured with bortezomib when cells from the same donor were used as stimulating cells. By contrast, when third-party donor cells were used as stimulating cells, no significant differences were observed between T lymphocytes previously exposed or not to the drug, indicating a highly specific depletion of T lymphocytes alloreactive against primary donor antigens. The addition of bortezomib decreased not only the proliferation and viability of activated T lymphocytes but also the levels of IFNγ and IL-2, which were significantly decreased among activated T cells cultured with bortezomib at doses ranging from 10 to 100 nM. In conclusion, at concentrations reached in the clinical setting, bortezomib induces selective apoptosis and decreases Th1 response among alloreactive T lymphocytes while it barely affects unstimulated T cells. These results establish the basis for the clinical use of bortezomib in the management of graft-versus-host disease (GVHD).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2005-05-2118

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 193

Metadata

Authors
Blanco, B., Pérez-Simón, J. A., Sánchez-Abarca, L. I., Carvajal-Vergara, X., Mateos, J., Vidriales, B., López-Holgado, N., Maiso, P., Alberca, M., Villarón, E., Schenkein, D., Pandiella, A., & Miguel, J. S.
Venue
Blood
Published
2006-05-01
Volume
107
Issue
9
Pages
3575-3583
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2133590829
Cited by
193
References
4
FWCI
3.76
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. https://app.cochat.ai/papers/10.1182/blood-2005-05-2118
The paper
Blanco, B., Pérez-Simón, J. A., Sánchez-Abarca, L. I., Carvajal-Vergara, X., Mateos, J., Vidriales, B., López-Holgado, N., Maiso, P., Alberca, M., Villarón, E., Schenkein, D., Pandiella, A., & Miguel, J. S. (2006). Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood. https://doi.org/10.1182/blood-2005-05-2118

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.